EUVIMEDEUVIMED entdecken
Open Access

Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets

Samuel L M Raines, Shane D Falcinelli, Jackson J Peterson, Ellen Van Gulck iD, Brigitte Allard, Jennifer Kirchherr, Jerel Vega, Isabel Najera, Daniel Boden, Nancie M Archin iD, David M Margolis iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00201-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Samuel L M Raines und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, HIV Infections, HIV-1, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited cellular levels of the HIV transcriptional activator Tat are one contributor to proviral latency that might be targeted in HIV cure strategies. We recently demonstrated that lipid nanoparticles containing HIV tat mRNA induce HIV expression in primary CD4 T cells. Here, we sought to further characterize tat mRNA in the context of several benchmark latency reversal agents (LRAs), including inhibitor of apoptosis protein antagonists (IAPi), bromodomain and extra-Terminal motif inhibitors (BETi), and histone deacetylase inhibitors (HDACi). tat mRNA reversed latency across several different cell line models of HIV latency, an effect dependent on the TAR hairpin loop. Synergistic enhancement of tat mRNA activity was observed with IAPi, HDACi, and BETi, albeit to variable degrees. In primary CD4 T cells from durably suppressed people with HIV, tat mRNA profoundly increased the frequencies of elongated, multiply-spliced, and polyadenylated HIV transcripts, while having a lesser impact on TAR transcript frequencies. tat mRNAs alone resulted in variable HIV p24 protein induction across donors. However, tat mRNA in combination with IAPi, BETi, or HDACi markedly enhanced HIV RNA and protein expression without overt cytotoxicity or cellular activation. Notably, combination regimens approached or in some cases exceeded the latency reversal activity of maximal mitogenic T cell stimulation. Higher levels of tat mRNA-driven HIV p24 induction were observed in donors with larger mitogen-inducible HIV reservoirs, and expression increased with prolonged exposure time. Combination LRA strategies employing both small molecule inhibitors and Tat delivered to CD4 T cells are a promising approach to effectively target the HIV reservoir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsHIV InfectionsHIV-1Nanoparticlestat Gene Products, Human Immunodeficiency VirusVirus LatencyHumansAnti-HIV AgentsCD4-Positive T-LymphocytesHIV AntigensRNA, Messenger

Stichwörter der Autor:innen

HIVTatlatencylipidnanoparticlesreversal

Substanzen

Anti-HIV AgentsHistone Deacetylase InhibitorsHIV AntigensRNA, Messengertat Gene Products, Human Immunodeficiency Virus

Autor:innen und Institutionen

  • Department of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Janssen Infectious Diseases, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Arcturus Therapeutics, Science Center Drive, San Diego, California, USA.

ORCID-Profile: Ellen Van Gulck, Nancie M Archin, David M Margolis

Förderung

  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NIAID NIH HHS

Zitieren

APA

Raines, S. L. M., Falcinelli, S. D., Peterson, J. J., Van Gulck, E., Allard, B., Kirchherr, J., Vega, J., Najera, I., Boden, D., Archin, N. M., & Margolis, D. M. (2024). Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00201-24

Vancouver

Raines SLM, Falcinelli SD, Peterson JJ, Van Gulck E, Allard B, Kirchherr J, et al. Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00201-24

BibTeX
@article{Raines2024,
  author = {Raines, Samuel L M and Falcinelli, Shane D and Peterson, Jackson J and Van Gulck, Ellen and Allard, Brigitte and Kirchherr, Jennifer and Vega, Jerel and Najera, Isabel and Boden, Daniel and Archin, Nancie M and Margolis, David M},
  title = {Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00201-24}
}
Kostenlos starten →